THE NATIONAL INSTITUTE OF HEALTH AND CARE, England, recommended Eribulin for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimen for advanced disease. In the European Union, The DRUG is indicated as at least one chemotherapeutic regimen and marketing authorization was granted in 2014.... […]
NOVOGEN Ltd. and Genentech entered an agreement to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase pathway. Genentech is a member of the Roche Group. Novogen is an Australian-based company. The lead indication for GDC-0084 is glioblastoma multiforme. GDC-0084 is distinguished from most molecules in the class by its ability to cross... […]
PRONAI THERAPEUTICS INC. announced that it has obtained an exclusive license from the CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737 (formerly CCT245737), a highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1 (Chk1). PNT737 is being investigated in two recently initiated Phase I clinical trials, currently sponsored and... […]
NCI ANNOUNCED A COLLABORATION with the Multiple Myeloma Research Foundation to incorporate MMRF's genomic and clinical data about the disease into the NCI Genomic Data Commons, a publicly available database that promotes the sharing of genomic and clinical data among researchers and facilitates precision medicine in oncology.
THE PRIX GALIEN FOUNDATION announced the nominees for its “Discovery of the Decade” awards covering distinguished industry achievement in medical innovation. This recognition is being held under the sponsorship of the Foundation’s Awards Committee, comprising of nine leaders from academia and industry, including four Nobel Laureates. After ten years of annual awards, the Prix Galien... […]
GENOMICS ENGLAND is partnering with GenomOncology LLC to use GenomOncology’s Knowledge Management System to analyze cancer samples in the 100,000 Genomes Project. This partnership will couple Genomics England curated database with the GO KMS’s clinical reporting data for a comprehensive clinical report comprised of the most relevant drugs, prognoses, and clinical trials. The GO KMS... […]
BOEHRINGER INGELHEIM and ViraTherapeutics announced a long-term collaboration to develop a next-generation oncolytic virus therapy platform and to investigate the ViraTherapeutics lead candidate VSV-GP (Vesicular Stomatitis Virus glycoprotein) alone and in combination with other therapies. ViraTherapeutics has developed its technology with joint support from its lead investors EMBL Ventures and Boehringer Ingelheim Venture Fund and... […]
JANSSEN RESEARCH & DEVELOPMENT LLC said a supplemental New Drug Application for ibrutinib (Imbruvica) has been submitted to FDA for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy. The filing is based on data from the multi-center, open-label Phase II PCYC-1121 trial ((NCT01980628) assessing the use of ibrutinib, a BTK... […]
DIGNITY HEALTH and Catholic Health Initiatives announced the launch of the Precision Medicine Alliance LLC, which will offer patients from both health care systems faster and more accurate diagnostic and treatment protocols based on their genetic and molecular profile information.
THE ONCOLOGY RESEARCH INFORMATION EXCHANGE NETWORK (ORIEN) and HudsonAlpha Institute of Biotechnology announced a new collaboration to advance cancer research and care called The ORIEN Avatar Research Program. Under the agreement, HudsonAlpha will provide DNA sequences for 20,000 patient samples, tumor and non-tumor, by 2019 to identify the genetic disturbances and mutations of each patient’s... […]
